JP2002212067A - Composition for treating cold - Google Patents
Composition for treating coldInfo
- Publication number
- JP2002212067A JP2002212067A JP2001006659A JP2001006659A JP2002212067A JP 2002212067 A JP2002212067 A JP 2002212067A JP 2001006659 A JP2001006659 A JP 2001006659A JP 2001006659 A JP2001006659 A JP 2001006659A JP 2002212067 A JP2002212067 A JP 2002212067A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cold
- treating
- group
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims abstract description 8
- 229960002071 bepotastine Drugs 0.000 claims abstract description 8
- 206010039083 rhinitis Diseases 0.000 claims abstract description 7
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960005405 methoxyphenamine Drugs 0.000 claims abstract description 6
- OEHAYUOVELTAPG-UHFFFAOYSA-N methoxyphenamine Chemical compound CNC(C)CC1=CC=CC=C1OC OEHAYUOVELTAPG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001802 phenylephrine Drugs 0.000 claims abstract description 6
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims abstract description 6
- 229960000395 phenylpropanolamine Drugs 0.000 claims abstract description 6
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims abstract description 6
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 claims description 5
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 claims description 5
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 5
- 229960003592 fexofenadine Drugs 0.000 claims description 5
- 229960002221 methylephedrine Drugs 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 208000024891 symptom Diseases 0.000 abstract description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000000043 antiallergic agent Substances 0.000 description 4
- -1 chewables Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000000150 Sympathomimetic Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 210000002850 nasal mucosa Anatomy 0.000 description 3
- 230000001975 sympathomimetic effect Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 206010028741 Nasal inflammation Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 2
- 229940108858 belladonna total alkaloid Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229960000354 fexofenadine hydrochloride Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229940064707 sympathomimetics Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- QDPOOGQUCJJZAO-FCXRPNKRSA-N [(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QDPOOGQUCJJZAO-FCXRPNKRSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960001543 isopropamide iodide Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960000659 methoxyphenamine hydrochloride Drugs 0.000 description 1
- FGSJNNQVSUVTPW-UHFFFAOYSA-N methoxyphenamine hydrochloride Chemical compound Cl.CNC(C)CC1=CC=CC=C1OC FGSJNNQVSUVTPW-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、風邪による鼻炎症
状に対する効果が増強された風邪治療用組成物に関す
る。TECHNICAL FIELD The present invention relates to a composition for treating a cold, which has an enhanced effect on rhinitis caused by a cold.
【０００２】[0002]
【従来の技術及び発明が解決しようとする課題】風邪症
候群はウイルス性の呼吸器感染症である。一般に、上気
道を中心とする局所炎症性症状に発熱、倦怠感等の種々
の全身症状を伴う疾患である。風邪の治療法として、そ
の原因となるウイルスの感染及び増殖を抑制する抗ウイ
ルス作用を有する薬剤の開発が原因療法として望まれて
いるが、依然として有効なものがなく、個々の風邪症状
の改善を目的とする対症療法が中心となっている。多岐
に亘る風邪症状の治療には種々の薬効成分を含む配合剤
が有効とされるが、薬物の使用頻度を減らしかつ副作用
の発生を防止するためには、その成分として何を選ぶ
か、その成分を如何に配合して処方するかがポイントと
なっていた。BACKGROUND OF THE INVENTION The cold syndrome is a viral respiratory infection. Generally, it is a disease accompanied by various systemic symptoms such as fever, malaise, and local inflammatory symptoms centering on the upper respiratory tract. As a treatment for the common cold, the development of a drug having an antiviral effect that suppresses the infection and proliferation of the virus that causes the cold has been desired as a causal treatment. The main symptomatic treatment is aimed at. Combination preparations containing various medicinal ingredients are effective in treating a wide variety of cold symptoms.However, in order to reduce the frequency of drug use and prevent the occurrence of side effects, what kind of ingredients should be selected should be selected. The point was how to mix and formulate the components.
【０００３】ベポタスチン、フェキソフェナジンは抗ア
レルギー薬として用いられており、また、フェニルプロ
パノールアミン、メチルエフェドリン、フェニレフリ
ン、メトキシフェナミンは交感神経興奮薬として長い間
汎用されている薬剤である。[0003] Bepotastine and fexofenadine are used as antiallergic drugs, and phenylpropanolamine, methylephedrine, phenylephrine and methoxyphenamine have been widely used as sympathomimetics for a long time.
【０００４】しかし、（ａ）ベポタスチン又はフェキソ
フェナジンと（ｂ）フェニルプロパノールアミン、メチ
ルエフェドリン、フェニレフリン又はメトキシフェナミ
ンを組み合わせた組成物は知られていない。当然、この
（ａ）と（ｂ）の組成物が鼻炎症状に対する強い効果を
有することは知られていない。However, there is no known composition in which (a) bepotastine or fexofenadine is combined with (b) phenylpropanolamine, methylephedrine, phenylephrine or methoxyphenamine. Naturally, it is not known that the compositions (a) and (b) have a strong effect on rhinitis symptoms.
【０００５】本発明の目的は、風邪による鼻炎症状に対
する効果が増強された風邪治療用組成物を提供すること
である。It is an object of the present invention to provide a composition for treating a cold, which has an enhanced effect on rhinitis symptoms caused by the cold.
【０００６】[0006]
【課題を解決するための手段】本発明者らは、上記を目
的とし鋭意研究した結果、有効成分として、ある特定の
抗アレルギー薬と特定の交感神経興奮薬を配合した組成
物が鼻粘膜の炎症症状（充血、鼻閉など）の除去あるい
は軽減に対し優れた効果を示すことを見い出し、その知
見に基づき本発明を完成した。Means for Solving the Problems The inventors of the present invention have conducted intensive studies for the above purpose, and as a result, have found that a composition comprising a specific antiallergic drug and a specific sympathomimetic as the active ingredients has been applied to the nasal mucosa. The present inventors have found that they show an excellent effect on removing or reducing inflammatory symptoms (such as hyperemia and nasal congestion), and completed the present invention based on the findings.
【０００７】本発明の組成物の有効成分の一つとして配
合する抗アレルギー薬はベポタスチン、フェキソフェナ
ジン及びこれらの塩類からなる群より選ばれる１種以上
である。[0007] The antiallergic drug to be incorporated as one of the active ingredients of the composition of the present invention is at least one selected from the group consisting of bepotastine, fexofenadine and salts thereof.
【０００８】本発明の組成物の有効成分の一つとして配
合する交感神経興奮薬はフェニルプロパノールアミン、
メチルエフェドリン、フェニレフリン、メトキシフェナ
ミン及びこれらの塩類からなる群より選ばれる１種以上
である。[0008] Sympathomimetics incorporated as one of the active ingredients of the composition of the present invention include phenylpropanolamine,
One or more selected from the group consisting of methylephedrine, phenylephrine, methoxyphenamine and salts thereof.
【０００９】本発明において塩類とは、塩酸塩、硝酸
塩、硫酸塩、リン酸塩、シュウ酸塩、マレイン酸塩、フ
マル酸塩、トシル酸塩、臭化水素酸塩等が挙げられる。In the present invention, the salts include hydrochloride, nitrate, sulfate, phosphate, oxalate, maleate, fumarate, tosylate, hydrobromide and the like.
【００１０】[0010]
【発明の実施の形態】本発明の風邪治療用組成物は、通
常、成人に対して１日当たり１回ないし数回に分けて経
口投与することができる。この投与量は年齢、体重、病
状により適宜増減することができる。各成分の投与量
は、それぞれ成人に対して１日当たり、（ａ）ベポタス
チン（その塩類は有効部分）は２〜２０ｍｇがよく、フ
ェキソフェナジン（その塩類は有効部分）は１５〜１２
０ｍｇがよい。また、同様に、（ｂ）フェニルプロパノ
ールアミンは２０〜１００ｍｇがよく、メチルエフェド
リン（ｌ体、ｄｌ体を含む）は２２〜１１０ｍｇがよ
く、フェニレフリンは６〜４０ｍｇがよく、メトキシフ
ェナミンは３０〜１５０ｍｇがよい。BEST MODE FOR CARRYING OUT THE INVENTION The composition for treating a cold of the present invention can be usually orally administered to an adult once or several times a day. This dose can be appropriately increased or decreased depending on the age, weight, and medical condition. The dose of each component is preferably 2 to 20 mg per day for adult (a) bepotastine (the salt is an effective portion) and 15 to 12 mg for fexofenadine (the salt is an effective portion) per adult.
0 mg is good. Similarly, (b) phenylpropanolamine is preferably 20 to 100 mg, methylephedrine (including l-form and dl-form) is preferably 22 to 110 mg, phenylephrine is preferably 6 to 40 mg, and methoxyphenamine is 30 to 100 mg. 150 mg is good.
【００１１】本発明の風邪治療用組成物は、剤型として
錠剤、カプセル剤、顆粒剤、細粒剤、粉剤、チュアブル
剤、発泡剤、ドロップ剤、口中溶解剤、ドライシロップ
剤、内服液剤等の経口投与形態の製剤として用いる。こ
れらの製剤は、常法により調製することができる。[0011] The composition for treating a cold of the present invention may be used in the form of tablets, capsules, granules, fine granules, powders, chewables, foaming agents, drops, mouth dissolving agents, dry syrups, oral liquids and the like. It is used as an oral dosage form. These preparations can be prepared by a conventional method.
【００１２】固形剤においては製剤の調製に使用する担
体としては、乳糖、デンプン、砂糖、マンニトール、結
晶セルロースなどの賦形剤、ヒドロキシプロピルセルロ
ース、ヒドロキシプロピルメチルセルロース、ゼラチ
ン、ＰＶＰなどの結合剤、カルボキシメチルセルロース
カルシウム、低置換度ヒドロキシプロピルセルロースな
どの崩壊剤、ステアリン酸マグネシウム、硬化ヒマシ
油、タルクなどの滑沢剤があり、この他必要に応じて溶
解補助剤、緩衝剤、保存剤、香料、色素、矯味剤等を使
用することができる。In the case of solid preparations, the carriers used in the preparation of preparations include excipients such as lactose, starch, sugar, mannitol, crystalline cellulose, binders such as hydroxypropylcellulose, hydroxypropylmethylcellulose, gelatin, PVP, and carboxy. There are disintegrants such as methylcellulose calcium and low-substituted hydroxypropylcellulose, lubricating agents such as magnesium stearate, hydrogenated castor oil, and talc.In addition, if necessary, dissolution aids, buffering agents, preservatives, fragrances, and pigments And flavoring agents can be used.
【００１３】また、内服液剤においては製剤の調製に使
用する担体としては、ショ糖脂肪酸エステル類、ステア
リン酸ポリオキシル類、ポリオキシエチレンポリオキシ
プロピレングリコール類、ポリオキシエチレンモノ脂肪
酸エステル類等の界面活性剤、合成ケイ酸アルミニウ
ム、ケイ酸マグネシウム、炭酸マグネシウム、酸化マグ
ネシウム、メタケイ酸アルミン酸マグネシウム等の増粘
剤、クエン酸緩衝液、リン酸緩衝液等の有機酸系・無機
酸系のｐＨ調整剤があり、この他必要に応じて溶解補助
剤、緩衝剤、保存剤、香料、色素、甘味剤等を使用する
ことができる。[0013] In the liquid preparation for internal use, the carrier used for the preparation of the preparation includes sucrose fatty acid esters, polyoxyl stearate, polyoxyethylene polyoxypropylene glycols, and polyoxyethylene mono fatty acid esters. Agents, thickeners such as synthetic aluminum silicate, magnesium silicate, magnesium carbonate, magnesium oxide, and magnesium aluminate metasilicate; organic acid and inorganic acid pH adjusters such as citrate buffer and phosphate buffer In addition, if necessary, a solubilizing agent, a buffer, a preservative, a flavor, a pigment, a sweetener, and the like can be used.
【００１４】本発明の風邪治療用組成物は、以上の成分
の他に必要に応じて非ステロイド性抗炎症薬、消炎酵素
薬類、気管支拡張薬、他の中枢神経興奮薬、鎮咳薬、去
痰薬、抗ヒスタミン薬、他の抗アレルギー薬、抗コリン
薬、ビタミン類、制酸薬、生薬等から選ばれる少なくと
も１つの薬剤を適宜に配合しても良い。なお、これらの
成分は単独または相互に混合して用いることができ、通
常は一般用医薬品製造指針（２０００年版・薬事審査研
究会監修、株式会社じほう発行）に収載されているかぜ
薬基準、鼻炎用内服薬基準等に準拠して配合される。The composition for treating a cold according to the present invention may further comprise, if necessary, a nonsteroidal anti-inflammatory drug, an anti-inflammatory enzyme drug, a bronchodilator, another central nervous stimulant, an antitussive, an expectorant. At least one drug selected from drugs, antihistamines, other antiallergic drugs, anticholinergic drugs, vitamins, antacids, crude drugs and the like may be appropriately compounded. These components can be used singly or as a mixture of each other. Usually, cold medicine standards and rhinitis listed in the over-the-counter drug manufacturing guidelines (2000 edition, supervised by the Pharmaceutical Affairs Committee, published by Jiho Co., Ltd.) It is compounded in accordance with the standard for internal use.
【００１５】[0015]
【実施例】以下に実施例及び試験例を挙げて本発明をさ
らに詳しく説明するが、本発明はその例に限定されるも
のではない。The present invention will be described in more detail with reference to examples and test examples, but the present invention is not limited to these examples.
【００１６】実施例１ 下記の各成分及び分量を秤量し充分混合した後、打錠機
（クリーンプレス コレクト１９；菊水製作所社製）を
用いて錠剤を製した。なお、１錠重量２００ｍｇとし、
８ｍｍ径の隅角平面の杵を使用した。 ベシル酸ベポタスチン １０ｇ 塩酸フェニルプロパノールアミン １００ｇ 塩化リゾチーム １００ｇ（力価） 無水カフェイン ７５ｇ 乳糖 ２９５ｇ 微結晶セルロース（アビセルＰＨ２０１） ２９０ｇ ステアリン酸マグネシウム １０ｇExample 1 After the following components and amounts were weighed and thoroughly mixed, tablets were produced using a tableting machine (Clean Press Collect 19; manufactured by Kikusui Seisakusho). The weight of one tablet is 200 mg.
An 8 mm-diameter corner flat punch was used. Bepotastine besylate 10 g Phenylpropanolamine hydrochloride 100 g Lysozyme chloride 100 g (titer) Anhydrous caffeine 75 g Lactose 295 g Microcrystalline cellulose (Avicel PH201) 290 g Magnesium stearate 10 g
【００１７】実施例２ 下記の各成分及び分量を秤量し充分混合した後、実施例
１と同様にして、２００ｍｇの錠剤を得た。 ベシル酸ベポタスチン ２０ｇ 塩酸フェニルプロパノールアミン １００ｇ ベラドンナ総アルカロイド ０．４ｇ 塩化リゾチーム ９０ｇ（力価） 無水カフェイン ７５ｇ 乳糖 ２３３．６ｇ 微結晶セルロース ２２６ｇ ステアリン酸マグネシウム ２０ｇExample 2 The following components and amounts were weighed and thoroughly mixed, and a tablet of 200 mg was obtained in the same manner as in Example 1. Bepotastine besylate 20 g Phenylpropanolamine hydrochloride 100 g Belladonna total alkaloid 0.4 g Lysozyme chloride 90 g (titer) Anhydrous caffeine 75 g Lactose 233.6 g Microcrystalline cellulose 226 g Magnesium stearate 20 g
【００１８】実施例３ 下記の各成分及び分量を秤量し充分混合した後、実施例
１と同様にして、２００ｍｇの錠剤を得た。 塩酸フェキソフェナジン ６０ｇ ｄｌ−塩酸メチルエフェドリン ６０ｇ ベラドンナ総アルカロイド ０．３ｇ ブロメライン １０００００単位 タブレトーズ ９０ｇ 低置換度ヒドロキシプロピルセルロース ８２．７ｇ ステアリン酸マグネシウム １７ｇExample 3 The following components and amounts were weighed and thoroughly mixed, and a tablet of 200 mg was obtained in the same manner as in Example 1. Fexofenadine hydrochloride 60 g dl-Methylephedrine hydrochloride 60 g Belladonna total alkaloid 0.3 g Bromelain 100,000 units Tabretase 90 g Low-substituted hydroxypropylcellulose 82.7 g Magnesium stearate 17 g
【００１９】実施例４ 下記の各成分及び分量を秤量し均一に混合した後、実施
例１と同様にして、１５０ｍｇの錠剤を得た。 塩酸フェキソフェナジン １２０ｇ 塩酸メトキシフェナミン １５０ｇ ヨウ化イソプロパミド ７．５ｇ グリチルリチン酸ジカリウム（グリチルリチン酸として２００ｇ） 無水カフェイン ７５ｇ 乳糖 １８２．５ｇ 微結晶セルロース １８２ｇ ステアリン酸マグネシウム ２０ｇ 硬化ヒマシ油 ５ｇExample 4 The following components and amounts were weighed and uniformly mixed, and a 150 mg tablet was obtained in the same manner as in Example 1. Fexofenadine hydrochloride 120 g Methoxyphenamine hydrochloride 150 g Isopropamide iodide 7.5 g Dipotassium glycyrrhizinate (200 g as glycyrrhizic acid) Caffeic anhydride 75 g Lactose 182.5 g Microcrystalline cellulose 182 g Magnesium stearate 20 g Hardened castor oil 5 g
【００２０】試験例［日本白色雄性ウサギの鼻粘膜炎症
に対する作用］ （試験検体の調製方法）表１に示す各成分を採取し、結
晶セルロース１００ｍｇ、ステアリン酸マグネシウム１
５ｍｇ、乳糖５０ｍｇ及び硬化ヒマシ油５ｍｇと均一に
混合し、各群の試験検体とした。なお、コントロール群
の検体は上記基剤成分のみで製した。Test Example [Effect on Nasal Mucosal Inflammation of Japanese White Male Rabbit] (Preparation Method of Test Specimen) Each component shown in Table 1 was collected, and 100 mg of crystalline cellulose, 1 mg of magnesium stearate 1
5 mg, lactose 50 mg and hydrogenated castor oil 5 mg were uniformly mixed to prepare a test sample for each group. In addition, the sample of the control group was manufactured only from the above-mentioned base components.
【００２１】[0021]
【表１】単位：ｍｇ [Table 1] Unit: mg
【００２２】（試験方法）１２週齢の日本白色雄性ウサ
ギを１群３匹として用いた。各ウサギに、１鼻腔当た
り、２．０％カプサイシン水溶液の１０μＬを４時間間
隔で３回鼻腔内に噴霧し、鼻粘膜炎症反応を惹起した。
続いて、各試験検体の半量を８時間間隔で２回経口投与
し、２回目投与後１時間における症状を鼻腔内視鏡にて
観察した。評価法としては、０点；ほとんど充血してい
ない、１点；充血が認められる、２点；ほぼ全面が充血
している、３点；充血と粘液が認められる、４点；浮腫
が認められる、５点；浮腫により鼻腔が狭窄している、
の６段階で評価し、各群３匹の平均点を比較した。(Test Method) Japanese white male rabbits, 12 weeks old, were used as 3 rabbits per group. To each rabbit, 10 μL of a 2.0% aqueous solution of capsaicin was sprayed into the nasal cavity three times at 4-hour intervals per nasal cavity to induce an inflammatory reaction in the nasal mucosa.
Subsequently, a half amount of each test sample was orally administered twice at an interval of 8 hours, and symptoms at 1 hour after the second administration were observed with a nasal endoscope. Evaluation method: 0 point; hardly congested, 1 point; congestion observed, 2 points; almost congested, 3 points; congestion and mucus, 4 points, edema 5 points; nasal cavity narrowed due to edema;
And the average score of 3 mice in each group was compared.
【００２３】（結果）図１に示す通り、組合せ処方群
（Ａ〜Ｂ群）の方が単味群（Ｃ〜Ｅ群）及びコントロー
ル群より評価点が著しく低く，組合せ処方に鼻粘膜炎症
に対する優れた効果があることが示された。(Results) As shown in FIG. 1, the combination prescription group (groups A and B) had a significantly lower evaluation score than the plain group (groups C to E) and the control group. It was shown to have excellent effects.
【００２４】[0024]
【発明の効果】本発明は、鼻粘膜の炎症症状の除去・軽
減に対し優れた効果を有する組成物であり、風邪による
鼻炎等に対して有効な薬剤を提供することができた。Industrial Applicability The present invention is a composition having an excellent effect on the removal and reduction of inflammatory symptoms of the nasal mucosa, and was able to provide a drug effective against rhinitis due to a cold.
【００２５】[0025]
【図１】は各試験検体の鼻粘膜炎症に対する効果の比較
を示す。FIG. 1 shows a comparison of the effect of each test sample on nasal mucosal inflammation.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 中神 浄二 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 (72)発明者 中川 泰緒 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 (72)発明者 相川 勝義 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 Ｆターム(参考） 4C206 AA01 AA02 FA10 FA11 FA14 MA03 MA04 MA72 NA14 ZA34 ZA59 ZC54 ──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Joji Nakagami 3- 24-1, Takada, Toshima-ku, Tokyo Inside Taisho Seiyaku Co., Ltd. (72) Inventor Yasushi Nakagawa 3--24, Takada, Toshima-ku, Tokyo No. 1 Taisho Pharmaceutical Co., Ltd. (72) Inventor Katsuyoshi Aikawa 3-24-1, Takada, Toshima-ku, Tokyo F-term (reference) 4C206 AA01 AA02 FA10 FA11 FA14 MA03 MA04 MA72 NA14 ZA34 ZA59 ZC54
Claims (3)
及びこれらの塩類 （ｂ）フェニルプロパノールアミン、メチルエフェドリ
ン、フェニレフリン、メトキシフェナミン及びこれらの
塩類において、（ａ）の群から選ばれる１種以上及び
（ｂ）の群から選ばれる１種以上を配合した風邪治療用
組成物。(A) Bepotastine, fexofenadine and salts thereof (b) phenylpropanolamine, methylephedrine, phenylephrine, methoxyphenamine and salts thereof, wherein at least one selected from the group (a) and A composition for treating a cold, comprising one or more members selected from the group (b).
の風邪治療用組成物。2. The composition for treating a cold according to claim 1, wherein the dosage form is an oral administration form.
を用いる鼻炎症状の治療方法。3. A method for treating rhinitis using the composition for treating a cold according to claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001006659A JP2002212067A (en) | 2001-01-15 | 2001-01-15 | Composition for treating cold |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001006659A JP2002212067A (en) | 2001-01-15 | 2001-01-15 | Composition for treating cold |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002212067A true JP2002212067A (en) | 2002-07-31 |
Family
ID=18874514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001006659A Withdrawn JP2002212067A (en) | 2001-01-15 | 2001-01-15 | Composition for treating cold |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002212067A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1314400C (en) * | 2004-12-29 | 2007-05-09 | 杭州容立医药科技有限公司 | Solid preparation taken through oral cavity of compound MEthoxyphEnaminE and preparation method |
| WO2008123701A1 (en) * | 2007-04-05 | 2008-10-16 | Hanmi Pharm. Co., Ltd. | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same |
| JP2016222657A (en) * | 2015-06-01 | 2016-12-28 | ロート製薬株式会社 | Anti-allergic composition |
| JP6286096B1 (en) * | 2017-08-01 | 2018-02-28 | ロート製薬株式会社 | Pharmaceutical tablets |
| JP2019147797A (en) * | 2018-02-26 | 2019-09-05 | ロート製薬株式会社 | Granule containing fexofenadine hydrochloride |
| JP2020070285A (en) * | 2017-12-27 | 2020-05-07 | 興和株式会社 | Pharmaceutical product |
| JP2021091623A (en) * | 2019-12-09 | 2021-06-17 | 興和株式会社 | Pharmaceutical |
-
2001
- 2001-01-15 JP JP2001006659A patent/JP2002212067A/en not_active Withdrawn
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1314400C (en) * | 2004-12-29 | 2007-05-09 | 杭州容立医药科技有限公司 | Solid preparation taken through oral cavity of compound MEthoxyphEnaminE and preparation method |
| WO2008123701A1 (en) * | 2007-04-05 | 2008-10-16 | Hanmi Pharm. Co., Ltd. | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same |
| JP2016222657A (en) * | 2015-06-01 | 2016-12-28 | ロート製薬株式会社 | Anti-allergic composition |
| JP6286096B1 (en) * | 2017-08-01 | 2018-02-28 | ロート製薬株式会社 | Pharmaceutical tablets |
| JP2019026609A (en) * | 2017-08-01 | 2019-02-21 | ロート製薬株式会社 | Pharmaceutical tablet |
| JP2020070285A (en) * | 2017-12-27 | 2020-05-07 | 興和株式会社 | Pharmaceutical product |
| JP7274288B2 (en) | 2017-12-27 | 2023-05-16 | 興和株式会社 | pharmaceuticals |
| JP2019147797A (en) * | 2018-02-26 | 2019-09-05 | ロート製薬株式会社 | Granule containing fexofenadine hydrochloride |
| JP2021091623A (en) * | 2019-12-09 | 2021-06-17 | 興和株式会社 | Pharmaceutical |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190039769A (en) | Treatment of eosinophilic esophagitis | |
| US20220110945A1 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| JP2012001558A (en) | Novel combination of loteprednol and antihistamine | |
| JP2001199882A (en) | Composition for cold and rhinitis | |
| JP7243876B2 (en) | solid formulation | |
| JP2002348240A (en) | Pharmaceutical composition | |
| JP2002316927A (en) | Composition for common cold | |
| JP2002332229A (en) | Composition for common cold | |
| JP2002212067A (en) | Composition for treating cold | |
| JP2003089638A (en) | Pharmaceutical composition | |
| JP2002255816A (en) | Composition for treating cold | |
| US8529946B2 (en) | Rapidly disintegrating antihistamine formulation | |
| JP6258264B2 (en) | Compositions and methods for increasing human platelet levels | |
| JP2001097856A (en) | Antitussive | |
| Hanson | Cough mixtures-an overview | |
| JP2003012514A (en) | Medicament composition | |
| JP2013049729A (en) | Pharmaceutical composition | |
| JP2002363072A (en) | Antitussive composition | |
| JP3987501B2 (en) | Pharmaceutical composition | |
| JP2000044463A (en) | Rapidly dissolvable tablet | |
| JP2003104903A (en) | Antitussive composition | |
| JP4710240B2 (en) | Pharmaceutical composition | |
| JPH0967256A (en) | Drug for common cold | |
| JP2003081828A (en) | Medicine composition | |
| JP2001089375A (en) | Composition for common cold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20060324 |